Abstract:Background: The genomic delineation of breast cancer is a novel approach to evaluating the disease. The opportunities arising from this genomic data analysis help in identifying specific cell line models and subtypes that are key for preclinical studies, developing predictive biomarkers, new target agents, and informing therapy selection. There is a wealth of information in previously collected datasets from breast cancer patients, but this has been under-studied and information on clinical association from these datasets has been limited. Triple-Negative Breast Cancer (TNBC) has been especially notorious since a large number of young premenopausal women diagnosed with the disease have suffered a worse outcome than the other known breast cancer types and there is no targeted and effective therapy for the treatment of the disease. This approach of taking a closer look at the genomics of TNBC will help in moving toward the often-cited dream of personalized medicine in difficult to treat areas of breast cancer, more specifically in our case, Triple Negative Breast Disease. However, the adaptation of genomic data into treatment regimens customized or tailor-made for each individual patient has been restricted in part, due to uncertainties in diverging from guideline-based clinical protocols. We report the Genomic Approach to TNBC in the context of predicting favorable outcomes to treatment responses and briefly describe recurrence-related data. Patients and Methods: We studied data derived from three different gene expression profiling platforms. We identified 486 samples associated with disease response to therapy and selected them for in-depth analyses. Hence 3 independent sets of analyses were carried out for each different platform due to the fact that each of these platforms had gene expression profiles that were populated with the TNBC cases with specific neo-adjuvant therapies namely, Platinum-based cohort [referring to HGU133plus2 platform related samples], taxane cohort [referring HGU133A platform samples] and anthracyclines with or without taxane cohort [HTA2.0 array] respectively. We aimed to analyze recurrence data, however, it was sparse amounting to 50 samples in total across the various publicly available datasets and we could analyze the same only but could not make definitive conclusions owing to the small sample size. Results: In the platinum-based cohort, pathway enrichment analysis using Cluster Profiler revealed the enrichment of key terms like Platinum drug resistance, chemical carcinogenesis, glutathione metabolism-related terms in no response category. In the Taxane-based cohort, pathway enrichment analysis revealed a defined enrichment of oncogenic signaling pathways like Pi3K-AKT, ECM, Focal adhesion in the no response category and the Anthracycline with or without taxane cohort showed that while enrichment of Wnt and TGF beta signaling were observed in no response category the response group was seen populated with immune response-related pathways. Conclusions: Chemotherapy is an important treatment option and is currently the mainstay in cases of Triple-Negative Breast Cancer. It was shown to reduce one-third of the annual death rate regardless of tumour characteristics. Chemotherapy is used as the mainstay in cases of triple-negative disease, HER2-positive tumors and high-risk oestrogen positive tumors. Significant toxicity associated with the therapy aside, not every patient benefits compulsorily from it and there is a sheer dearth of both practically validated and theoretically proven predictive markers to allow the tailoring of chemotherapy regimens to each individual patients needs or tumour type. Achieving pathological complete response (pCR) is associated with favorable outcomes, however, its predictive power in being used as a surrogate endpoint for improved overall survival (OS) has been debated. TNBC and breast cancer in general, need to be viewed in the context of underlying genomic phenotypes. Based on this notion, treatment decisions should be less influenced by guidelines based on set clinical protocols and rather be more driven by tumour biology if we are to improve the response to chemotherapy

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer

Superior Outcome after Neoadjuvant Chemotherapy with Docetaxel, Anthracycline, and Cyclophosphamide Versus Docetaxel Plus Cyclophosphamide: Results from the NATT Trial in Triple Negative or HER2 Positive Breast Cancer

The Effect of Delayed Adjuvant Chemotherapy on Relapse of Triple-Negative Breast Cancer.

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Regional differences in neo/adjuvant chemotherapy timing in patients with early-stage triple-negative breast cancer in England

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Impacts of Tumor Stage at Diagnosis and Adjuvant Therapy on Long-Term Survival Outcomes in Patients with Triple-Negative Breast Cance Achieving Pathologic Complete Response After Neoadjuvant Chemotherapy

Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer

The advance of adjuvant treatment for triple-negative breast cancer

Abstract P4-12-19: Impact of Delaying Initiation of RT Following Definitive Surgery or Following Adjuvant Chemotherapy on Survival Outcomes in Breast Cancer Patients

Effects of Adjuvant Chemotherapy in T1N0M0 Triple-Negative Breast Cancer.

Impact of Tumour Genomics on Response to Standard Neo-adjuvant Chemotherapy in Triple-Negative Breast Cancer

Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors

Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes

Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer

Response to Neoadjuvant Therapy and Disease Free Survival in Patients with Triple-Negative Breast Cancer.

Curative effect of TAC neoadjuvant chemotherapy on patients with triple negative breast cancer

Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data